Age-related macular degeneration is a leading cause of visual impairment and severe vision
loss. Clinically, it is classified as early-stage (medium-sized drusen and retinal pigmentary …

Diabetic retinal disease is envisioned to become the plague of the coming decades with a
steep increase of worldwide diabetes incidence followed by a substantial rise in retinal …

Purpose The complement pathway may play a key role in the pathogenesis of age-related
macular degeneration (AMD). The safety and efficacy of avacincaptad pegol (Zimura …

OBJECTIVE: Two similarly designed, phase-3 studies (VEGF Trap-Eye: Investigation of
Efficacy and Safety in Wet AMD [VIEW 1, VIEW 2]) of neovascular age-related macular …

Purpose To provide 2-year results comparing anti–vascular endothelial growth factor
(VEGF) agents for center-involved diabetic macular edema (DME) using a standardized …

Purpose To assess long-term outcomes 7 to 8 years after initiation of intensive ranibizumab
therapy in exudative age-related macular degeneration (AMD) patients. Design Multicenter …

Intravitreal anti-vascular endothelial growth factor (VEGF) drugs have revolutionized the
treatment of neovascular age-related macular degeneration (NVAMD). However, many …

Age-related macular degeneration (AMD), a progressive condition that is untreatable in up
to 90% of patients, is a leading cause of blindness in the elderly worldwide. The two forms of …

Purpose To determine efficacy and safety of intravitreal aflibercept in patients with
neovascular age-related macular degeneration (AMD) during a second year of variable …

Background Visual impairment in elderly people is a considerable health problem that
significantly affects quality of life of millions worldwide. The magnitude of this issue is …